<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03428321</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL17_0436</org_study_id>
    <nct_id>NCT03428321</nct_id>
  </id_info>
  <brief_title>Small and Steatotic Hepatocellular Carcinoma</brief_title>
  <official_title>Small and Steatotic Hepatocellular Carcinoma : a Distinctive Radiological Variant With Improved Outcome After Percutenous Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous thermoablation in an effective local curative treatment in patients with&#xD;
      cirrhosis and HCC smaller than 3 cm in diameter (BCLC 0-A).&#xD;
&#xD;
      Around 30% of HCC patients referred for percutaneous ablation were regarded as non-feasible&#xD;
      because of a difficult-at risk location or undetectable nodules.&#xD;
&#xD;
      We used percutaneous thermoablation to treat HCC on high risk locations (subcapsular or liver&#xD;
      dome) with or without lipiodol marked (for undetectable HCC).&#xD;
&#xD;
      No clinical study has been published so far to compare percutaneous thermoablation of HCC on&#xD;
      liver dome CT guided with artificial pneumothorax and lipiodol marked, and percutaneous&#xD;
      thermoablation of HCC guided by ultrasonography (non subcapsular, distent form diaphragm).&#xD;
&#xD;
      This retrospective study evaluate the overall survival, the local tumor progression or&#xD;
      distant liver progression after percutaneous ablation for HCC and determine prognostic&#xD;
      factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We performed 412 percutaneous thermoablations on 238 patients for HCC between January 2015&#xD;
      and November 2019.&#xD;
&#xD;
      All thermoablation procedures were performed percutaneously under ultrasound or CT guidance,&#xD;
      with ou without artificial pneumothorax or ascites, with ou without lipiodol marked.&#xD;
&#xD;
      Purposes:&#xD;
&#xD;
        -  Tumor response upon mRECIST criteria&#xD;
&#xD;
        -  Progression-free survival&#xD;
&#xD;
        -  Overall survival&#xD;
&#xD;
        -  Local tumor progression&#xD;
&#xD;
        -  Distent liver progression&#xD;
&#xD;
        -  Prognostic factors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thermal ablations</measure>
    <time_frame>1 day</time_frame>
    <description>Evaluation of thermal ablations (radiofrequency and microwave ablation)</description>
  </primary_outcome>
  <enrollment type="Actual">238</enrollment>
  <condition>HCC</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who underwent one or several percutaneous thermoablations for HCC form January&#xD;
        2015 to November 2019 at the Department of Radiology St-Eloi University Hospital -&#xD;
        Montpellier School of Medicine France.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  HCC according to histological examination or Barcelona criteria&#xD;
&#xD;
          -  BCLC0 or A&#xD;
&#xD;
          -  Measurable targets according to mRECIST v1.1&#xD;
&#xD;
          -  Child A or B7 cirrhosis&#xD;
&#xD;
          -  HCC &lt; 4 cm, &lt; 3 nodules, Age ≥ 18 years&#xD;
&#xD;
          -  No extrahepatic metastasis, no vascular invasion&#xD;
&#xD;
          -  Performance status 0 or 1&#xD;
&#xD;
          -  Thrombocytes ≥ 50 000/mm3, TP &gt; 50%&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Follow-up &lt; 1month&#xD;
&#xD;
          -  Lobar/main portal venous thrombus&#xD;
&#xD;
          -  Abundant ascites&#xD;
&#xD;
          -  Antecedent of bilio-digestive anastomosis or endoscopic sphincterotomy&#xD;
&#xD;
          -  Combined treatment with embolization or chemo-embolization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BORIS GUIU, PU-PH</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microwave ablation</keyword>
  <keyword>Percutaneous thermalablation</keyword>
  <keyword>High risk location</keyword>
  <keyword>Articifial pneumothorax</keyword>
  <keyword>Lipiodol marked</keyword>
  <keyword>Prognostic factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

